Quốc gia: Malaysia
Ngôn ngữ: Tiếng Anh
Nguồn: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
UROFOLLITROPIN
BSV BIOSCIENCE MALAYSIA SDN. BHD.
UROFOLLITROPIN
1vial Vials; 1ml mL
BHARAT SERUMS AND VACCINES LTD.
ROUTE OF ADMINISTRATION: Intramuscular (IM) + Subcutaneous (SC). CONTRAINDICATION: _FOLICULIN_ is contraindicated in women who exhibit: 1. High levels of FSH, indicating primary ovarian failure. 2. Uncontrolled thyroid or adrenal dysfunction. 3. An organic intracranial lesion such as pituitary tumor. 4. The presence of any cause of infertility other than anovulation unless they are candidates for in vitro fertilization. 5. Ovarian cysts or enlargement not due to ovarian polycystic ovarian disease. 6. Prior hypersensitivity to Urofollitropin. 7. Foliculin is contraindicated in women who are pregnant. There are limited human data on the effects of Foliculin when administered during pregnancy. Contraindicated for safety reasons in gynecological hemorrhages of unknown aetiology. WARNINGS AND PRECAUTIONS: Before starting treatment, the couple's infertility should be assessed as appropriate and putative contra-indications for pregnancy evaluated. Adherence to the recommended dosage and monitoring schedules will minimize the possibility of ovarian hyperstimulation syndrome. Excessive ovarian response to _FOLICULIN_ treatment does generally not induce significant adverse effects except if hCG is administered for ovulation induction or if pregnancy occurs; ovarian hyper stimulation syndrome occurs usually 1 to 2 weeks following hCG administration and ovulation. In case of symptoms such as pelvic pain, abdominal distension or ovarian enlargement or if oestrogen assays or ultrasound examinations suggest an excessive oestrogenic response, Foliculin administration should be discontinued and hCG should not be administered and intercourse avoided in order to prevent ovarian hyperstimulation. Ascites, pericardial effusion, hydrothorax, hemo-concentration, secondary hyperaldosteronism or hypercoagulability might appear. These symptoms should be controlled through appropriate medical measure, including avoidance of unnecessary pelvic examination. In the absence of pregnancy, they usually resolve spontaneously with the onset of the Đọc toàn bộ tài liệu